Prometheus Biosciences Inc
NASDAQ:RXDX
Prometheus Biosciences Inc
NASDAQ:RXDX
Price:
199.92 USD
0.09%
Updated:
May 17, 2024
Balance Sheet
Balance Sheet Decomposition
Prometheus Biosciences Inc
Prometheus Biosciences Inc
| Current Assets | 726.4m |
| Cash & Short-Term Investments | 713.7m |
| Other Current Assets | 12.7m |
| Non-Current Assets | 32m |
| PP&E | 31m |
| Other Non-Current Assets | 971k |
| Current Liabilities | 19.3m |
| Accounts Payable | 1.2m |
| Accrued Liabilities | 17m |
| Other Current Liabilities | 1.2m |
| Non-Current Liabilities | 41.5m |
| Other Non-Current Liabilities | 41.5m |
Balance Sheet
Prometheus Biosciences Inc
Prometheus Biosciences Inc
Currency: USD
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
11
|
4
|
54
|
257
|
292
|
|
| Cash Equivalents |
11
|
4
|
54
|
257
|
292
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
403
|
|
| Total Receivables |
0
|
0
|
1
|
1
|
1
|
|
| Accounts Receivables |
0
|
0
|
1
|
1
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
33
|
2
|
7
|
11
|
|
| Total Current Assets |
11
|
38
|
57
|
265
|
708
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
32
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
32
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
|
| Intangible Assets |
0
|
5
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
7
|
2
|
1
|
1
|
|
| Total Assets |
11
N/A
|
50
+354%
|
60
+18%
|
268
+349%
|
741
+177%
|
|
| Liabilities | ||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
1
|
|
| Accrued Liabilities |
0
|
3
|
6
|
11
|
21
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
5
|
6
|
0
|
0
|
|
| Other Current Liabilities |
0
|
23
|
3
|
4
|
2
|
|
| Total Current Liabilities |
1
|
32
|
15
|
16
|
23
|
|
| Long-Term Debt |
0
|
8
|
11
|
0
|
0
|
|
| Other Liabilities |
0
|
4
|
5
|
16
|
42
|
|
| Total Liabilities |
1
N/A
|
44
+3 397%
|
31
-29%
|
33
+5%
|
65
+99%
|
|
| Equity | ||||||
| Common Stock |
18
|
44
|
126
|
0
|
0
|
|
| Retained Earnings |
8
|
37
|
99
|
189
|
331
|
|
| Additional Paid In Capital |
0
|
0
|
2
|
424
|
1 007
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
10
N/A
|
7
-31%
|
28
+321%
|
235
+726%
|
676
+187%
|
|
| Total Liabilities & Equity |
11
N/A
|
50
+354%
|
60
+18%
|
268
+349%
|
741
+177%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
37
|
37
|
37
|
39
|
47
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
